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KAJIAN PERSPEKTIF KEATAS KESAN STATIN TERHADAP 
DAPATAN KLINIKAL DALAM KALANGAN PESAKIT GINJAL KRONIK – 
TANPA DIALISIS: PERBANDINGAN DIANTARA SEBUAH HOSPITAL DI 
MALAYSIA DAN ARAB SAUDI 
 
ABSTRAK 
Penyakit Ginjal Kronik (CKD) adalah kebimbangan kesihatan global yang 
merupakan sebahagian besar daripada beban penyakit di seluruh dunia. Untuk 
mengawal kemajuan CKD, banyak strategi telah dicadangkan. Walau bagaimanapun, 
masih banyak soalan yang perlu dijawab dalam segmen amalan klinikal ini 
terutamanya di negara-negara seperti Kerajaan Arab Saudi (KSA) dan Malaysia. 
Sebagai contoh, penggunaan statin untuk pesakit CKD masih kontroversi kerana bukti 
yang bercanggah. Juga, Kualiti Hidup Kehidupan (HRQOL) pesakit CKD bukan 
dialisis tidak dinilai di negara yang disebut dahulu. Tambahan pula, Sikap dan Persepsi 
Pengetahuan (KAPs) Profesional Penjagaan Kesihatan (HCP) di Malaysia dan KSA 
belum dinilai walaupun HCP terutamanya ahli nefrologi merupakan teras utama 
pelaksanaan garis panduan CKD yang sesuai. Oleh itu, matlamat kajian ini adalah 
untuk mengkaji kesan renoprotektif dan komplikasi pelbagai dos / jenis statin (lengan 
A kajian), untuk menilai kualiti hidup yang berkaitan dengan kesihatan pesakit ND-
CKD Malaysia dan Saudi (lengan B), dan menilai ahli farmasi dan pakar perubatan 
dan kesedaran mengenai penggunaan statin dalam pesakit CKD di hospital dan 
penjagaan kesihatan Malaysia dan hospital Saudi (arm C). Bagi lengan A (penggunaan 
statin), 455 pesakit dari Hospital Pulau Pinang (HPP), Pulau Pinang, Malaysia, dan 
431 pesakit dari Program Keselamatan Angkatan Keselamatan (SFHP) di Riyadh, 




pengecualian kajian dimasukkan. Reka bentuk prospektif kajian yang diamati telah 
diterima pakai di mana peserta kajian diikuti pada garis dasar, selang tiga, enam, dan 
sembilan bulan. Hanya atorvastatin 40 mg menunjukkan kalium yang lebih tinggi dan 
tahap urea yang jauh lebih rendah daripada plasebo. Selain itu, tidak terdapat 
perbezaan yang signifikan dalam kesan Simvastatin 20mg apabila digunakan dalam 
populasi Malaysia dan Saudi. Bagi lengan B (HRQOL), seramai 526 orang pesakit 
tidak dialisis di kalangan pesakit CKD di Malaysia dan 301 pesakit Saudi dimasukkan 
untuk mengisi borang soal selidik yang disahkan SF-36. Reka bentuk penyelidikan 
rentas keratan telah digunakan untuk menilai kesan CKD pada skor HRQOL di 
kalangan pesakit CKD dialisis di HPP di Pulau Pinang, Malaysia, dan SFHP di Riyadh, 
KSA. Umur muda, tempoh dan peringkat CKD yang lebih rendah, pendapatan lebih 
tinggi, dan tahap pendidikan yang lebih tinggi semuanya dikaitkan dengan skor 
HRQOL yang lebih tinggi. Kesimpulannya, pemerhatian ini menunjukkan kesan kuat 
ND-CKD pada HRQOL. Kajian lanjut untuk merancang dan menilai campur tangan 
yang berpotensi bagi peningkatan HRQOL dalam pesakit ND-CKD adalah wajar. 
Untuk lengan C (KAPs), Reka bentuk rentas keratan dipakai menggunakan soal selidik 
sendiri yang dibina dan disahkan sebelum kajian dijalankan. Soal selidik diedarkan 
kepada 187 HCP di SFHP di Riyadh, Arab Saudi, dan 122 HCP di HPP di Pulau 
Pinang, Malaysia. Jurnal perubatan telah dipilih sebagai sumber asas untuk maklumat 
CKD yang dikemas kini di Malaysia dan KSA (masing-masing 30% dan 39%). Lebih 
daripada 90% daripada mereka bersetuju dengan keperluan rujukan awal pesakit CKD 
kepada seorang ahli nefrologi. Umur yang lebih tua, doktor pakar, pengalaman lebih 
lama, gaji tertinggi secara konsisten berkaitan dengan skor yang lebih tinggi. Akhir 




mengenai CKD dan penggunaan statin. HCP dari kedua-dua negara mempunyai sikap 



























PROSPECTIVE STUDY ON STATINS EFFECT ON CLINICAL OUTCOMES 
AMONG NON-DIALYSIS CKD PATIENTS: A COMPARISON BETWEEN A 





Chronic Kidney Disease (CKD) is a global health concern which constitutes a 
considerable share of the diseases burden around the world. For controlling the 
progress of CKD, many strategies have been proposed. However, there are still many 
questions to be answered in this segment of clinical practice especially in countries 
like the Kingdom of Saudi Arabia (KSA) and Malaysia. For instance, the use of statins 
for CKD patients is still controversial due to contradictory evidence. Also, the Health-
Related Quality of Life (HRQOL) of non-dialysis CKD patients has not been assessed 
in the formerly mentioned countries. Furthermore, the Knowledge Attitudes and 
Perceptions (KAPs) of Healthcare Professionals (HCPs) in Malaysia and KSA have 
not been evaluated even though HCPs especially nephrologists are the mainstay of the 
appropriate CKD guidelines implementation. Therefore, the aims of this study are to 
investigate the renoprotective effect and complications of different doses/types of 
statins (arm A of the study), to evaluate the health-related quality of life of Malaysian 
and Saudi ND-CKD patients (arm B), and to assess pharmacists and physicians 
knowledge and awareness about using statin in CKD patients in the Malaysian and the 
Saudi hospitals and healthcare settings (arm C). For arm A (statin use), 455 patients 
from Hospital Pulau Pinang (HPP), Penang, Malaysia, and 431 patients from Security 
Forces Hospital Program (SFHP) in Riyadh, KSA who were taking statins (different 
types and doses) and satisfied the inclusion and the exclusion criteria of the study were 




participants were followed on the baseline, three, six, and nine months intervals. Only 
atorvastatin 40 mg showed significantly higher potassium and significantly lower urea 
level than placebo. Furthermore, there was no significant difference in the impact of 
Simvastatin 20mg when used in Malaysian and Saudi population. For arm B 
(HRQOL), A total of 526 non-dialysis CKD Malaysian patients and 301 Saudi patients 
were included to fill out the SF-36 validated questionnaire. A cross-sectional research 
design was used to assess the effect of CKD on HRQOL scores among non-dialysis 
CKD patients at HPP in Penang, Malaysia, and the SFHP in Riyadh, KSA. Young age, 
lower CKD duration and stage, higher income, and higher educational level were all 
associated with higher HRQOL scores. In conclusion, these observations highlight the 
strong impact of ND-CKD on HRQOL. Further studies to design and evaluate 
potential interventions for improvement of HRQOL in ND-CKD patients are 
warranted. For arm C (KAPs), A cross-sectional design was employed using a self-
administered questionnaire that was constructed and validated before the study. The 
questionnaire was distributed to 187 HCPs at SFHP in Riyadh, Saudi Arabia, and 122 
HCPs at HPP in Penang, Malaysia. Medical journals were chosen as the fundamental 
source for updated CKD information in both Malaysia and KSA (30% and 39% 
respectively). More than 90% of them agreed with the necessity of early referral of 
CKD patients to a nephrologist. Older age, specialist physicians, longer experiences, 
highest salaries were consistently related to higher scores.  Lastly, there is room for 
improvement of CME programs, and HCPs knowledge regarding CKD and the use of 
statins. HCPs from both countries hold a positive attitude/Perceptions towards statins 




  CHAPTER ONE  
    INTRODUCTION 
     1.1 General Introduction 
             Chronic kidney disease (CKD) is a major public health problem (James et 
al., 2010). Cardiovascular disease (CVD) continues to be the leading cause of 
morbidity and mortality among people with CKD worldwide, with rates of 
cardiovascular events and mortality consistently increasing as kidney function 
declines (Friel, 2014, Go et al., 2004). Dialysis patients have mortality rates up to 
40-fold higher than the general population, with CVD being responsible for up to 
50% of these deaths (Sarnak, 2000).   
 
Patients with CKD have a higher prevalence of a number of risk factors 
for CVD, including lipid abnormalities, hypertension, obesity, and diabetes. 
Kidney Disease Outcome Quality Initiative (K/DOQI) clinical practice 
guidelines have recommended statin therapy for the prevention of CVD in 
patients with CKD and high-low density lipoprotein cholesterol (LDL-C) levels 
(Snyder, 2009). However, the value of this approach continues to be debated, 
particularly in those with the most advanced kidney dysfunction. Levels of 
cholesterol in patients with kidney disease do not always have the same log-linear 






The burden of CVD may not be predominantly due to atherosclerotic 
disease in people with severely decreased GFR when compared with people with 
normal renal function. Emerging data suggest the pattern of cardiovascular 
pathology may be different in advanced CKD, with vascular stiffness and 
calcification, structural heart disease, and sympathetic overactivity contributing 
to an increased risk of cardiac arrhythmia and heart failure (Foley, 1998).  
              
            1.2 Chronic Kidney Disease (CKD) Definitions 
Kidney disease can either be acute or chronic. In acute kidney injury 
(AKI), there is a reversible decline in kidney function, whereas chronic kidney 
disease (CKD) is the progressive destruction of kidney mass through loss of 
nephrons and irreversible sclerosis over a period of months or years 
(Venkatachalam, 2010, López-Novoa, 2010). 
 
CKD can also lead to end-stage renal disease (ESRD), due to which the 
patients normally require dialysis and renal transplantation. Both dialysis and 
renal transplantation are termed as renal replacement therapy (RRT). RRT has a 
considerable effect on the patient quality of life (QoL) as well as survival 
(Bellomo, 2004).  
 
CKD is defined as abnormalities of kidney structure or function, present 
for 3 months, with implications for health (Xie et al, 2017). The definition of 
CKD remains intact. The addition of ‘with implications on health’ is intended to 
reflect the notion that a variety of abnormalities of kidney structure or function 
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may exist, but not all have implications for the health of individuals, and therefore 
need to be contextualized. Kidney damage refers to a broad range of 
abnormalities observed during the clinical assessment, which may be insensitive 
and non-specific for the cause of disease but may precede reduction in kidney 
function. Excretory, endocrine and metabolic functions decline together in most 
CKD patients. Glomular Filtration Rate (GFR) is generally accepted as the best 
overall index of kidney function. It is known that a GFR 60 ml/min/ 1.73m2 as 
decreased GFR and a GFR 15 ml/min/ 1.73m2 as kidney failure (Matsushita et 
al., 2012). 
 
1.3 Global Burden of Chronic Kidney Disease  
Chronic kidney disease is a major problem with a worldwide prevalence 
that varies from country to country ((Vos, 2015). The median prevalence of CKD 
in individuals aged ≥ 30 years old was 7.2%, while its prevalence in persons aged 
≥ 64 years old ranged from 23.4-35.8% (Mula-Abed, 2012). In the U.S., the 
prevalence of stage 5 CKD (kidney failure or hemodialysis) is 0.1% of the U.S. 
population and the prevalence of mild to severe disease (CKD stages 1 to 4) is 
11% of the U.S. population (Pitt, 1999, Harper, 2010). Chronic dialysis is 
annually associated with mortality rate approximately up to 20% (Go, 2004) 
 
CKD is also a devastating socio-economic problem across the world. The 
global annual growth rate of CKD is 8%, while annual dialysis growth rates are 
6-8% per annum. Disease of the genitourinary system is the 12th and 17th cause 




The lifetime of chronic kidney failure is one among fifty during the age 
of 40 years (Huang, 2006). The global burden of disease study in 2010 reported 
that CKD stands 27th among the global list of total death causes in 1990 but in 
2010 it becomes increased and ranked 18th (annual death rate 16.3 per 100 000) 
(Garrido, 2015). Chronic kidney failure enlisted 5th as the most common reason 
of death in some developing countries like South America (Colombia, Costa 
Rica, El Salvador, Mexico, and Venezuela), Andean (Bolivia, Ecuador, and Peru) 
and Latin America (Moncayo, 2017).  
 
1.4 Treatment/ Prevention of chronic kidney disease  
Proper management can possibly decrease the advancement of CKD and 
also decrease the risk of mortality due to CVD. The most important is to control 
the blood pressure of CKD patients with drugs which block the renin-angiotensin 
pathway, and control blood glucose level (James, 2014). The lipid level will 
decrease in CKD patients as a result of treating hyperlipidemia, which will further 
reduce the chances of atherosclerosis and CVD in CKD patients (Sarnak, 2003). 
Most suitable and easy tool is maintaining a normal level of protein and salt 
(James, 2014). CKD can be controlled by various approaches which include 
blood-pressure control, adherence to treatment, glycemic control, information 
about the disease, dietary habits, and lifestyle by self-management and health-
related professionals (Von, 1997). In order to treat CKD patients, a 
multidisciplinary approach should be followed to get better outcomes (James, 




1.5 Statins and Chronic Kidney Disease 
 In the general population, beneficial effects of statin treatment on 
cardiovascular endpoints are well established (Ridker, 2008). Chronic kidney 
disease (CKD) is a status of specific lipid disturbances, dyslipidemia with 
increased levels of triglycerides (TG), small dense and oxidized LDL (oxLDL), 
and lower high-density lipoprotein (HDL) cholesterol levels. In nephrotic 
syndrome, also total cholesterol and LDL levels are elevated (Agarwal, 2007).  
As patients with CKD and albuminuria have an increased incidence of 
cardiovascular disease, they should be considered for statin therapy. However, 
currently, only 25% of CKD patients are under continuous statin therapy. The 
indirect and direct effects of lipids on glomerular structure have been described 
in detail in animal models of renal damage (Kasiske et al., 1990) as well as in 
human subjects (Keane et al., 1990). Therefore, in theory, beneficial systemic and 
renal effects of lipid-lowering in CKD by statins could be expected. In fact, there 
are indeed well-proven general effects of statins in CKD patients, lipid-lowering, 
anti-inflammatory and anti-oxidative effects (Campese, 2007). 
 
The relative decrease in cardiovascular risk by statins diminishes in 
magnitude as kidney function declines, even after allowing for the smaller 
reductions in LDL cholesterol obtained in more advanced CKD. In patients on 
maintenance dialysis, several large randomized trials and high-quality meta-
analyses revealed that statins have little or no effect on cardiovascular outcome, 
despite significant LDL cholesterol lowering (Herrington, W., et al, 2016). These 
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counterintuitive findings have been attributed to the poor association of LDL 
cholesterol with cardiovascular risk in the dialysis population, owing to the 
predomination of nontraditional risk factors (e.g., mineral and bone metabolism 
disorder and oxidative stress) and nonatherosclerotic cardiac events (e.g., 
arrhythmia and heart failure) drowning out classic atherosclerotic disease 
(Kassimatis, T.I., et al, 2014). Chronic kidney disease is characterised by either 
reduced glomerular filtration rate (GFR) or significant proteinuria. This is 
associated with increased cardiovascular mortality, which becomes more than 10-
fold greater in those on dialysis compared with the general population (Herzog, 
C.A., et al, 2011). Renal transplantation lowers this risk, but cardiovascular disease 
remains the leading cause of death for transplant patients (Israni, A.K., et al, 2010). 
  
A characteristic pattern of lipid abnormalities affects those with chronic 
kidney disease (Keane, W.F., et al, 2012) and is implicated in the high rates of 
cardiovascular morbidity and mortality in this population (de Jager, D.J., et 
al,2009). Traditional cardiovascular risk factors such as diabetes and hypertension 
also contribute. These are prevalent in the chronic kidney disease population 
along with the proposed cardiovascular risk associated with oxidative stress, 
inflammation, insulin resistance, anaemia and disturbances of mineral 
metabolism. 
Although statins reduce cardiovascular disease in those at increased risk, 
(Cannon, C.P., et al, 2015) their effect is less clear in people with chronic kidney 





Few studies have looked specifically at lipid-lowering therapy in patients 
with chronic kidney disease. Most evidence is derived from subgroup or post hoc 
analyses. 
 
Patients not on dialysis 
A meta-analysis of statin efficacy in non-dialysis chronic kidney disease 
stages 1–5 reported an overall decreased risk for cardiovascular mortality and 
non-lethal cardiovascular events.  Statins resulted in a RR* of 0.72 (95% CI† 
0.66–0.79) for major cardiovascular events, 0.55 (95% CI 0.42–0.72) for 
myocardial infarction, 0.79 (95% CI 0.69–0.91) for all-cause mortality and an 
uncertain effect on stroke (RR 0.62, 95% CI 0.35–1.12). Adverse events with 
statins included elevated creatinine kinase and liver function abnormalities. There 
was no evidence of an effect on renal function (Athyros, V.G., et al, 2015). 
  
The benefit of statins appears to diminish with progression of chronic 
kidney disease. This probably contributes to the inconsistent relationship in 
studies between cholesterol-lowering therapy and cardiovascular outcome in 
chronic kidney disease (Zhang, X., et al, 2014). In a more recent meta-analysis, 
statin therapy reduced the risk of first major vascular event by 21% (RR 0.79, 
95% CI 0.77–0.81) per mmol/L reduction in LDL cholesterol. Smaller relative 
effects on major vascular events, major coronary events and vascular mortality 





The SHARP trial, (Baigent, C., et al, 2011) which enrolled patients with 
pre-dialysis chronic kidney disease and those on dialysis, evaluated daily 
simvastatin 20 mg plus ezetimibe 10 mg or placebo. In the pre-dialysis cohort of 
6247 patients (mean GFR of 26.6 mL/min/1.73 m2), LDL cholesterol fell by 0.85 
mmol/L over five years. These patients had a 17% RR reduction in major 
atherosclerotic events (RR 0.83, 95% CI 0.74–0.94) compared with placebo and 
the number needed to treat was 48. This compares favourably with numbers 
needed to treat in primary prevention studies of statins in the general population 
(Downs, J.R., et al,1998). There was a significant reduction in non-haemorrhagic 
stroke (RR 0.75, 95% CI 0.60–0.94) and in arterial revascularisation procedures 
(RR 0.79, 95% CI 0.68–0.93), but no effect on progression of chronic kidney 
disease (Haynes, R., et al, 2014).  
 
The rate of adverse events in the SHARP trial was low – myopathy was 
reported in 0.02% of patients and there was no evidence of increased hepatitis, 
gallstones, pancreatitis or malignancy in the lipid-lowering group. While this is 
the largest trial of lipid-lowering drugs in patients with chronic kidney disease to 
date, it failed to evaluate the role of a statin or ezetimibe alone. Other trials of 
lipid-lowering therapy in non-dialysis chronic kidney disease show considerable 






Patients on dialysis 
In addition to the SHARP trial, (Baigent, C., et al, 2011) there have been 
two major placebo-controlled randomised trials of statin therapy in haemodialysis 
patients – 4D (Wanner, C., et al, 2005) and AURORA (Fellström, B.C., et al, 2009) 
. The 4D study evaluated the effect of 20 mg atorvastatin on cardiovascular 
disease and death. It included only patients with diabetes and a high 
cardiovascular disease burden. Despite a profound reduction of LDL cholesterol 
early in the trial, there was no significant impact on major cardiovascular events 
or all-cause mortality. A higher rate of haemorrhagic stroke was observed in the 
atorvastatin group. Post hoc analysis revealed that atorvastatin was beneficial 
with respect to cardiac events and all-cause mortality in patients with a high 
baseline LDL (März, W., et al, 2011).  
 
AURORA investigated the effect of rosuvastatin in haemodialysis 
patients and likewise found no significant impact on major cardiovascular events 
(Fellström, B.C., et al, 2009). The study also reported an increased incidence of fatal 
haemorrhagic stroke with rosuvastatin in patients with diabetes, reinforcing the 
adverse outcomes noted in the 4D study. While the SHARP trial reported a 
reduction in major atherosclerotic events in the study population overall, a 
subgroup analysis of those on dialysis revealed no benefit (RR 0.9, 95% CI 0.75–






A recent meta-analysis conducted by the Cholesterol Treatment Trialists’ 
Collaboration indicated there was no benefit in terms of major vascular events, 
major coronary events or vascular mortality to support statin use in dialysis 
patients (Haynes, R., et al, 2014).   
 
Statin therapy appears to offer some benefit in patients with renal disease 
who are not on dialysis and to a more limited extent after transplant. There is no 
evidence to support commencing statins in that receiving dialysis. Evidence 
supports the safety of statins in chronic kidney disease, but caution is advised 
with high doses and when there is a potential for drug–drug interactions. 
 
 1.6 Chronic Kidney Disease in Malaysia and Saudi Arabia 
The Malaysian dialysis registry has demonstrated the rapid growth of 
dialysis provision in this country. This has been particularly dramatic in the older 
age groups. It has also shown that diabetic nephropathy leading to ESRD is on 
the rise and accounts for more than 50% of all incident dialysis patients. Hence 
prevention of ESRD is eminently achievable with better management of diabetes 
mellitus (Lim et al, 2008). On the other hand, Singapore aimed to assess the 
prevalence and risk factors of CKD in a multi-ethnic Asian population. They 
studied 4499 participants, aged 24-95 years. The age, sex-standardized 
prevalence of CKD was 12.8% (11.4%, 18.6% and 17.6% in Chinese, Malays, 
and Indians respectively). Older age and the presence of diabetes, hypertension, 
and dyslipidemia were significantly associated with CKD in all ethnic groups. 
Diabetes (45%) and dyslipidemia (16%) among Malays and hypertension among 
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Indians (23%) had a greater population- attributable risk of CKD (Villa-Zapata 
et al, 2016).  
 
As the world’s population ages and the diabetes epidemic continues 
unabated, chronic kidney disease (CKD) is emerging as an important non-
communicable disease worldwide (Levey et al, 2007). The three very important 
risk factors for CKD – diabetes, hypertension, and obesity– are highly prevalent 
in the Arab world, more so than perhaps anywhere else (Hooi et al, 2013). 
 
Progression of CKD to end-stage renal failure (ESRF) has tremendous 
human and economic implications. Mortality is as much as 17-fold higher in 
patients with ESRF compared to age- and gender-matched healthy individuals 
and the cost of dialysis or transplantation is frequently unaffordable to many in 
the absence of governmental programs (Hassanien et al, 2012). 
Data available on the exact prevalence of various kidney diseases in the 
Arab world is very limited. Reviewing the recent literature illustrated that there 
is no Arab country with up-to-date information on the epidemiology of CKD. 
Most of the data come from small studies of approximately 100 patients or less. 
Based on their size and other design considerations, data from these studies have 
limited generalizability (Farag et al, 2012). Prevalence (95% confidence interval 
(CI)) of all stages CKD was 9.4%. In Hail, Saudi Arabia (Ahmed et al, 2014), 
while the overall prevalence of CKD was 5.7% in Riyadh, Saudi Arabia 
(Alsuwaida et al, 2010). There is a lack of accurate data on the CKD prevalence 
(Ahmed et al, 2014). 
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1.7 Problem Statement 
There is a shortage in previous studies that have evaluated the 
renoprotective impact of statins and their risk factors and complication in CKD 
patients in Malaysia and Saudi Arabia, also there are limitations in previous 
studies that evaluate the quality of life of CKD patients and that assess the 
knowledge of healthcare team professionals about using of statins among CKD 
patients. The relation between the renal protective effect of different statins and 
different doses of the same statin has not been reported yet. 
 
In the past few years, several large-scale trials of statin therapy in people 
with CKD have been completed, including the recent large SHARP (Study of 
Heart and Renal Protection) trial (Baigent et al, 2011).  Although some of these 
trials have shown benefit, (Baigent et al, 2011), others have shown no effect 
(Fellström et al, 2009), leading to uncertainty about the presence and magnitude 
of renal protective effects and therefore difficulties for clinicians in the 
interpretation of the results into clinical practice (Jun et al, 2010).  
 
Two recent reviews have investigated the effect of statin in patients with 
CKD. However, both have not evaluated the effect of kidney function on statin 
therapy (Palmer et al, 2012, Upadhyay et al, 2012). No data are available on the 





1.8 Significance of the Study 
The majority of studies about the use of statins among non-dialysis CKD 
patients and quality of life of patients are conducted in developed countries and 
among the patients on dialysis, but there is limited data on statin use among CKD 
patients in Malaysia and Saudi Arabia. Research results on the renoprotective 
effect of statins among non-dialysis CKD patients and quality of life of the 
patients in Malaysia and Saudi Arabia could be used for better treatment and 
prevention of CKD progression in this population. The unique characteristics of 
this population could also be used for participation in global trials and a better 
understanding of the progression of CKD in those countries. 
 
Limited data are available about the using of statins among non-dialysis 
CKD patients in Malaysia and Saudi Arabia, and there is probably no information 
on baseline characteristics, in-hospital outcomes, quality of life outcomes, and 
the renal protective outcomes of statins of the non-dialysis CKD patients. This 
information could assist in distinguishing between the renal protective effect of 
different doses or different generic types of statins among the non-dialysis CKD 
patients. 
 
In addition, there are no data about the effect of CKD on the health-related 
quality of life of non-dialysis CKD patients in Malaysia and Saudi Arabia. These 
results could help to improve the quality of life of patients by finding the factors 
that affect the level of quality of life of those patients and create new interventions 
to improve it. 
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There is probably no information about the knowledge of healthcare team 
professionals about the importance and the benefit of using statins among non-
dialysis CKD patients. Obtaining these data could increase the awareness about 
the use of statins among this population and assists in early detection and 
prevention of the disease progression. 
 
To achieve the goals of this study, the three arms (aspects) of the study 
were integrated. First the study of the renoprotective effect of statins found the 
best statin to decrease CKD progression in parallel enhancing the HRQoL ,by 
knowing the factors that affect it,of non dialysis CKD patients would decrease 
CKD progression also.  Early referral of CKD patients to nephrologists would 
also decrease CKD progression this information would be collected from KAP 
survey (Figure 1.1).  
 
 










Health Care Professional 
(HCP)  
Pharmacist and Physician 
Health Related Quality 
of Life (HRQoL)  
Non-Dialysis CKD Patients 
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1.9 Study Objectives (figure 1.2) 
1.9.1 General Objectives 
1. To determine and compare the relationship between statin use and the 
progression of renal dysfunction among non-dialysis CKD patients 
receiving statins in Saudi Arabia and Malaysia. 
2. To evaluate the quality of life of non-dialysis CKD patients who used 
statins in Malaysia and Saudi Arabia. 
3. To assess pharmacist and physician knowledge, attitude and perception 
about the use of statin in non-dialysis CKD in Malaysia and Saudi Arabia. 
 
1.9.2 Specific Objectives 
1. To investigate the risk factors and complications of statins use among 
non-dialysis CKD patients. 
2. To compare the Reno-protective effect of different doses of Atorvastatin 




      Figure 1.2: Study Objectives  
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non-Dialysis CKD 
patient 
To determine the 
relationship between 
statin, use and the 





To compare the 
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and Practice of HCP 
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1.10 The Framework of Thesis 
To meet the objectives of this thesis, assessment of the renal protective 
effect of statin use among non- dialysis CKD patients, health-related quality of 
life and knowledge, attitude and perception of healthcare professionals about the 
use of statins among non-dialysis CKD patients have been narrated in this thesis 
(Figure 1.3). 
The first chapter is an orientation chapter in which background about 
CKD was introduced. This section sketches the global burden of chronic 
kidney disease and the relation between statins and chronic kidney disease. The 
significance of the study, statement of the problem was presented. Following 
that, the objectives of the current study are formulated and presented. Lastly, 
t h e  visual presentation on the current study’s organization was provided. 
Statins and clinical outcomes of non-dialysis CKD: 
The second chapter comprises a review of the literature related to the 
current study. This contains a review of the research paradigm. Next, an 
overview of the major issues related to CKD is provided. Of importance, this 
section also presented the statins effect on cardiovascular and renal 
outcomes. The clinical characteristics of in-hospital outcomes and 
pharmacology treatment of non-dialysis CKD shown in this chapter. Also, a 
comprehensive discussion of the data collection procedures and strategies were 
illustrated. Then the results of the research hypothesis have been mentioned and 
the answers achieved through several research analysis procedures.  
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Patient health-related quality of life and non-dialysis CKD: 
The third chapter, A research review of health-related quality of life issues 
was discussed and illustrated as well. It also is concerned with the methodology 
employed in this research. The research design employed in this study was 
described. Further, as this research aims to understand the effect of health-
related quality of life among non-dialysis CKD patients, a comprehensive 
discussion of the data collection procedures and strategies is illustrated.  
A section on pilot testing the instruments that were used in the study 
were illustrated. It also explains the sample size and population under the 
study. The experimental procedures that were carried out are explained as 
well. This chapter offers a discussion on the measurement tools utilized in this 
research as well. Particularly, the construction, validity, and reliability of 
measurement tools carried out in this research are also discussed. the statistical 
analysis procedures are discussed in this chapter. Finally, Each objective and its 
levels were presented in separate sections and statistical analysis employed is 
explained in each section. 
Knowledge, attitude and practice of health care professionals and statin use among 
non- dialysis CKD patients 
The fourth chapter A research review of KAP issues was discussed 
and illustrated as well. It also is concerned with the methodology employed in 
this research. The research design employed in this study is described. Further, 
as this research aims to understand the effect of Knowledge, attitude and practice 
of health care professionals and statin use among non-dialysis CKD patients, a 
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comprehensive discussion of the data collection procedures and strategies are 
illustrated.  
A section on pilot testing the instruments that were used in the study was 
illustrated. It also explains the sample size and population under the study. 
The experimental procedures that are carried out are explained as well. This 
chapter offers a discussion on the measurement tools utilized in this research as 
well. Particularly, the construction, validity, and reliability of measurement tools 
carried out in this research and the statistical analysis procedures were 
discussed in this chapter. Finally, each objective and its levels were presented in 
separate sections and statistical analysis employed is explained in each section. 
 
The fifth chapter presents the major conclusions and implications of the 
study. These conclusions and implications were important to know what the 
most important results were achieved and, importantly, drawn upon them a 
solid understanding of guidelines implementation and how functionally statins 
are operating in CKD context, the non-dialysis patients one in specific 
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Figure 1.3: Framework of Thesis 
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CKD is a major health problem across the globe (Schieppati, et al.,2005) 
and attention paid towards CKD is attributable to five factors, escalating 
prevalence, enormous treatment cost, recent data tell-tale problem that overt 
disease (stage 3 to 5) is merely the tip of iceberg of furtive disease (stage 1 to 2), 
its major involvement in increasing risk of cardiovascular events and discovery 
of effective measures to retard its progression (Sturm, 2002).  
 
CKD is a pathological condition which affects the morphology and 
efficiency of kidneys. The variation in disease expression is somehow related to 
various factors like cause, pathology, severity and also on the rate of progression 
(Petrosyan et al.,2016). CKD in the last 12 years has changed from life-
threatening to common manageable disorder (Jin, et al., 2016).  The development 
of CKD model, better guideline for definition and staging of CKD has aided in 
early detection and even in the prevention of CKD (Peralta et al.,2011, Klahr et 






Dyslipidemia is a major risk factor for cardiovascular morbidity and 
mortality and is common among patients with CKD. Lipid profiles vary widely 
in these patients, reflecting the level of kidney function and the degree of 
proteinuria (Holdaas et al., 2005). In general, the prevalence of hyperlipidemia 
increases as renal function declines, with the degree of hypertriglyceridemia and 
elevation of LDL cholesterol being proportional to the severity of renal 
impairment. 
Several factors contribute to the development dyslipidemia associated 
with chronic renal impairment. Patients with CKD have a reduction in the activity 
of lipoprotein lipase and hepatic triglyceride lipase. This interferes with uptake 
of triglyceride-rich, apolipoprotein B containing lipoproteins by the liver and in 
peripheral tissue, yielding increased circulation of these atherogenic lipoproteins. 
Hypercholesterolemia in nephrotic syndrome is thought to be due to increased 
production and decreased catabolism of lipoproteins. The degree of lipoprotein 
abnormality is roughly proportional to the amount of proteinuria and inversely 
proportional to serum albumin levels. However, infusions of albumin or dextran 
both normalize lipoprotein concentrations, suggesting that oncotic pressure 
changes rather than hypoalbuminemia signals increased lipoprotein synthesis by 
the liver. Additional data supporting this hypothesis is derived from in-vitro 
experiments demonstrating direct stimulation of increased hepatic 
apolipoprotein-B gene transcription in cells exposed to reduced oncotic pressure 
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(Yamauchi et al., 1992). Studies also suggest that hyperparathyroidism and the 
accumulation of calcium in pancreatic islet cells likely contribute to dyslipidemia 
of CKD as well (Arnadottir et al., 1995).  
 
Clinical trials in the general population have demonstrated that coronary 
heart disease mortality decreases proportional to LDL-cholesterol level 
reduction. Evidence for benefit of statins in reducing cardiovascular risk (i.e., 
composite outcomes) in CKD patients is less definitive. Recently, the largest 
clinical trial of statins in patients with stage 5 CKD (4D trial) was conducted in 
Germany, In this study, atorvastatin did not to reduce death from fatal stroke, 
nonfatal myocardial infarction, or nonfatal stroke in 200 patients with diabetes 
and stage 5 CKD (Wanner et al., 2005).  The results of the Study of Heart and 
Renal Protection (SHARP) provide further insight into the role of cholesterol 
lowering therapy in reducing cardiovascular events in kidney disease patients. 
SHARP is a prospective, randomized trial in which 9,000 patients with CKD and 
3,000 dialysis patients without coronary artery disease have been enrolled to 
assess the effects of lowering LDL-cholesterol with the combination of 
simvastatin and ezetimibe, with the primary outcome measure being the time to 
a first “major vascular event” defined as non-fatal myocardial infarction or 
cardiac death, non-fatal or fatal stroke, or an arterial revascularization procedure. 
The SHARP results show that lowering LDL cholesterol with the combination of 
simvastatin plus ezetimibe safely reduces the risk of major atherosclerotic events 
in a wide range of patients with chronic kidney disease. As in people without 
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kidney disease, the proportional reduction in major atherosclerotic events 
produced by a given absolute reduction in LDL cholesterol is broadly similar 
irrespective of age, sex, diabetes, history of vascular disease, and presenting lipid 
profile. The SHARP results are relevant, therefore, to most patients with chronic 
kidney disease, SHARP did not have sufficient power to assess the effects on 
major atherosclerotic events separately in dialysis and non-dialysis patients, but 
there was not good statistical evidence that the proportional effects in dialysis 
patients differed to those seen in patients not on dialysis. Moreover, since about 
a third of the patients who were not on dialysis at baseline began dialysis during 
the trial (with about one third of those doing so within the first year), the effects 
of simvastatin plus ezetimibe in the dialysis subgroup are reinforced by the 
favourable results in the non-dialysis subgroup. 
A relationship between total cholesterol levels and coronary heart disease 
(CHD) mortality as the primary outcome also has not been clearly established. In 
fact, several observational studies of stage 5 kidney disease patients suggest that 
lower total cholesterol levels are associated with higher mortality rate. For 
example, in a recent 10 -year prospective study the importance of total cholesterol 
levels on mortality was evaluated in 1,167 stage 5 kidney disease patients 
(Higashiuesato et al., 2002). Hypercholesterolemia (total cholesterol levels >200) 
was associated with increased all-cause mortality rate. Scintists suggests that 
decreased cholesterol and low cholesterol levels may be an indicator for poor 
health status. The clinical implication of the study was that individuals with 
spontaneously decreased cholesterol or persistently low cholesterol levels are at 
